FRACTYL HEALTH, INC.
Fractyl Health, Inc. (GUTS) is a small‑cap healthcare company developing endoscopic therapies aimed at treating metabolic diseases such as type 2 diabetes and obesity. The business focuses on minimally invasive procedures that seek to improve metabolic control as an alternative to pharmaceutical or surgical approaches. Investors should note Fractyl is in a development and early commercialisation phase: progress depends on clinical trial outcomes, regulatory decisions and payer reimbursement. With a market capitalisation of about $176.64 million, the stock can be volatile and is typically regarded as speculative. Key value drivers include trial readouts, regulatory milestones, partnership activity and adoption by clinicians and payers. Key risks include clinical setbacks, regulatory delays, funding requirements and potential dilution. This summary is for educational purposes only; it is not investment advice. Investors should consider their risk tolerance, time horizon and diversification needs, and consult a regulated financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying shares of Fractyl Health, anticipating significant price growth potential.
Financial Health
Fractyl Health, Inc. is generating modest revenue and cash flow, with a decent gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GUTS
Beyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: August 28, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory milestones could move the share price; outcomes are uncertain and the stock may be volatile.
Innovative therapy approach
Endoscopic metabolic treatments aim to offer a less invasive option to surgery, but commercial adoption depends on evidence, approvals and payer support.
Large potential market
If widely adopted, these treatments target a substantial global market for metabolic disease, though execution and reimbursement are key risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
